Marksans Pharma Ltd.
Snapshot View

62.90 -1.05 ▼-1.6%

27 January 2023, 04:01:00 PM
Volume: 418,787

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.marksanspharma.com
Market Cap 2,850.40 Cr.
Enterprise Value(EV) 2,602.11 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 4.39 Trailing Twelve Months Ending 2022-09
Price-Earning Ratio (PE) 14.34 Trailing Twelve Months Ending 2022-09
Industry PE 33.61 Trailing Twelve Months Ending 2022-09
Book Value / Share 26.53 Trailing Twelve Months Ending 2022-09
Price to Book Value 2.37 Calculated using Price: 62.95
Dividend Yield 0.40 Period Ending 2022-03
No. of Shares Subscribed 45.32 Cr. 453,163,746 Shares
FaceValue 1
Company Profile
Marksans Pharma, incorporated in 1992, was a wholly-owned subsidiary of Glenmark Pharmaceuticals. It became a separate entity in March 2003 and the name was changed to Marksans Pharma in 2005.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-1.64%
1 Week
-6.33%
1 Month
+4.83%
3 Month
+26.81%
6 Month
+28.24%
1 Year
+11.52%
2 Year
+15.73%
5 Year
+40.87%
10 Year
+2010.74%
9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 73.02 45.15 20.45 2.59 7.92 15.88 20.49 31.33 18.72
Return on Capital Employed (%) 38.30 44.64 23.16 3.99 10.60 18.51 25.57 39.76 23.82
Return on Assets (%) 16.52 19.21 11.86 1.54 4.83 10.49 14.17 22.40 13.04

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 142 380 454 433 471 542 636 887 1,202 1,263
Non Curr. Liab. 22 1 -2 16 16 17 24 24 57 64
Curr. Liab. 319 286 259 296 235 233 229 299 356 321
Minority Int. 7 8 8 6 10 10 13 19 21 19
Equity & Liab. 490 676 720 752 731 802 902 1,228 1,636 1,668
Non Curr. Assets 147 167 280 268 280 271 308 325 435 447
Curr. Assets 343 509 440 484 451 531 594 903 1,201 1,221
Misc. Exp. not W/O
Total Assets 490 676 720 752 731 802 902 1,228 1,636 1,668

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09 Rs. Cr. TTM
Net Sales 630 797 893 767 913 1,000 1,134 1,376 1,491 1,667
Other Income 7 12 13 19 8 5 0 7 42 58
Total Income 637 809 906 786 921 1,005 1,135 1,383 1,533 1,725
Total Expenditure -516 -621 -761 -734 -834 -868 -942 -1,037 -1,232 -1,392
PBIDT 121 188 145 52 87 137 193 346 301 333
Interest -19 -16 -10 -7 -10 -10 -9 -8 -8 -10
Depreciation -16 -16 -28 -30 -27 -23 -27 -36 -45 -55
Taxation -13 -44 -24 -4 -14 -24 -36 -64 -61 -69
Exceptional Items
PAT 74 112 83 11 36 80 121 239 187 198
Minority Interest -2 -3 -4 -3 -3 -4 -4 -3 -2 1
Share Associate
Other Related Items
Consolidated Net Profit 72 109 79 9 33 76 117 236 185 199
Adjusted EPS 2 3 2 0 1 2 3 6 5 5

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 39 65 155 31 14 50 27 233 179 99
Cash Fr. Inv. -5 -4 -33 -123 -21 -39 -13 -60 -45 -42
Cash Fr. Finan. -40 -29 17 -58 -3 3 -21 -114 -15 80
Net Change -7 31 138 -150 -10 15 -7 60 118 137
Cash & Cash Eqvt 16 47 185 35 25 40 33 94 212 349

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.60 49.00
Public 51.75 51.75 51.75 51.75 51.75 51.75 51.75 51.40 51.00
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Tue, 24 Jan 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Investors Meet
Tue, 24 Jan 2023
Submission Of Certificate From Statutory Auditor In Terms Of Regulation 169(5) Of The Securities And Exchange Board Of India (Issue Of Capital And Disclosure Requirements) Regulations 2018
Submission of Certificate from Statutory Auditor in terms of Regulation 169(5) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018
Mon, 23 Jan 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Marksans Pharma Limited announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution.

Technical Scans View Details >>

Wed, 25 Jan 2023
Close Crossing Last Week Low Close Crossing Last Week Low
Opening at High Opening at High
Making Lower Lows for 3 days Making Lower Lows for 3 days
Close Within 52 Week High Zone Close Within 52 Week High Zone
Close Below Last Week Low Close Below Last Week Low

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 249,518.84 1,040.75 +0.1%
Divi's Laboratories Ltd. 88,552.35 3,385.55 +1.5%
Cipla Ltd. 83,862.25 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. 69,879.98 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. 60,777.77 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. 52,497.96 1,537.85 -1.3%
Abbott India Ltd. 45,101.64 21,279.00 0.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 60.79 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 29.71 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-09 32.68 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-09 22.47 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 72.39 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-09 65.87 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-09 51.15 21,279.00 0.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 4.70 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 7.33 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-09 3.83 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-09 3.36 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.15 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-09 8.62 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-09 16.62 21,279.00 0.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 0.04 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 0.00 21,279.00 0.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 13.10 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 29.95 21,279.00 0.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 13.10 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 29.95 21,279.00 0.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 4,919.27 21,279.00 0.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 798.70 21,279.00 0.0%

FAQ's On Marksans Pharma Ltd.

What is Marksans Pharma share price?

Can I buy Marksans Pharma shares now?

What is the Dividend Yield of Marksans Pharma?

What is the Market Cap of Marksans Pharma?

What are the key metrics to analyse Marksans Pharma?

What is the 52 Week High and Low of Marksans Pharma?

What is the trend of Marksans Pharma share price?